update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.
Phio Pharmaceuticals Corp. PR Contact:
adams@bridgeviewmedia.com
PHIO PHARMACEUTICALS CORP.
CONSOLIDATED STATEMENTS OF OPERATIONS
(Amounts in thousands, except share and per share
data)
(Unaudited)
Year Ended
December 31,
-----------------------
2023 2022
---------- ----------
Operating expenses:
Research and development $ 6,332 $ 7,012
General and administrative 4,366 4,450
Loss on impairment of property and
equipment 126 --
--------- ---------
Total operating expenses 10,824 11,462
--------- ---------
Operating loss (10,824) (11,462)
Total other expense, net (2) (18)
--------- ---------
Net loss $ (10,826) $ (11,480)
========= =========
Net loss per common share:
Basic and diluted $ (5.20) $ (10.10)
========= =========
Weighted average number of common shares
outstanding
Basic and diluted 2,083,569 1,136,566
========= =========
PHIO PHARMACEUTICALS CORP.
CONSOLIDATED BALANCE SHEETS
(Amounts in thousands, except share data)
(Unaudited)
December 31, December 31,
2023 2022
-------------- --------------
ASSETS
Cash $ 8,490 $ 11,781
Restricted cash -- 50
Prepaid expenses and other current
assets 832 615
Right of use asset 33 161
Property and equipment, net 6 183
Other assets 3 24
---------- ----------
Total assets $ 9,364 $ 12,814
========== ==========
LIABILITIES, PREFERRED STOCK AND
STOCKHOLDERS' EQUITY
Accounts payable $ 657 $ 779
Accrued expenses 942 1,025
Lease liability 35 170
Total preferred stock -- 2
Total stockholders' equity 7,730 10,838
---------- ----------
Total liabilities, preferred stock
and stockholders' equity $ 9,364 $ 12,814
========== ==========
(END) Dow Jones Newswires
April 02, 2024 07:30 ET (11:30 GMT)
Comments